Clinical Trial Portfolio

Image credit: Lung cancer cells. Anne Weston, Francis Crick InstituteCC BY-NC

Open to recruitment


A randomised, open-label phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer.


MEDI4736 combinations in metastatic renal cell carcinoma.


A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer.


A novel, single arm phase II study for relapsed  germ cell tumours with poor prognosis.


An imaging feasibility study in oestrogen receptor negative MEtastatic breast cancer by Targeting integrin α-vβ6.


IMaging pilot study of the αvβ6 integrin radiotracer [18F]-A20FMDV2 in PAtients with solid Cancer Types.


Characterising metastatic penile cancer using molecular imaging - hybrid MRI-PET.


A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma.

In set up


A phase I study in patients with tumours requiring arginine to assess ADI-PEG 20 with Atezolizumab, Pemetrexed and Carboplatin (ADIAtezoPemCarbo).


A phase II, randomized study of paclitaxel weekly plus pembrolizumab versus paclitaxel weekly in ER-positive, Luminal B metastatic breast cancer.

In follow-up (closed to recruitment)


A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder.


Phase II window of opportunity study of short-term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer.


A phase II, open label, multicentre, randomised controlled trial comparing hyperthermia plus mitomycin to mitomycin alone, in patients with intermediate risk non-muscle invasive bladder cancer.


A randomized Phase II study of Fulvestrant in combination with the dual mTOR inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen receptor-positive advanced or metastatic breast cancer.


A Phase II, Double Blind, Randomised, Placebo-Controlled Study of the AKT Inhibitor AZD5363 in Combination with Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer.


Robotic Surgery After Focal Ablation Therapy.


A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab-Paclitaxel for pancreatic cancer.


A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers.


A phase II, single arm, multicentre trial of triamcinolone with a GnRH analog for castration resistant prostate cancer.